New anticancer agents in clinical development
Eckardt, J.; Eckhardt, G.; Villalona-Calero, M.; Drengler, R.; Von Hoff, D.
Oncology 9(12) 1321-1328; 1331; Discussion: 1332-1334
1995
ISSN/ISBN: 0890-9091 PMID: 8771106 Document Number: 449747
A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.